newsfilter
← Latest News
GlobeNewswire·

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

  • Roivant (NASDAQ: ROIV) will host a live conference call & webcast at 8:00 a.m. ET on Wednesday, May 20, 2026.
  • The event will report financial results for the fourth quarter & fiscal year ended March 31, 2026, while providing a business update.
  • Registration for the phone call is available via a provided link, with presentation details located in the Investors section of the Roivant website.
  • An archived webcast will be accessible on the company's website following the live event.
  • Roivant's pipeline includes brepocitinib for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, & lichen planopilaris.
  • The pipeline also features IMVT-1402 & batoclimab, monoclonal antibodies targeting FcRn for IgG-mediated autoimmune indications.
  • Mosliciguat, an inhaled sGC activator, is in development for pulmonary hypertension associated with interstitial lung disease.
  • The company advances its pipeline by creating nimble subsidiaries known as "Vants" & incubates discovery-stage companies & health technology startups.
  • The press release contains forward-looking statements subject to risks that could cause actual results to differ materially from expectations.
  • Investor inquiries should be directed to Keyur Parekh, while media inquiries should be directed to Stephanie Lee.